跳至主要内容
临床试验/CTRI/2024/12/078539
CTRI/2024/12/078539尚未招募Unknown

Prospective single arm, post marketing clinical study of REPER RPR-13 Hydrophobic Intraocular Lens to assess performance and safety in patients undergoing cataract surgery

Rayner Surgical India Pvt Ltd formerly Surgicon Healthcare Pvt Ltd1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年1月4日最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
50
试验地点
1
主要终点
To assess the intraoperative safety and performance of the Intraouclar Lens.

研究概览

简要总结

Hydrophobic Intraocular lenses are routinely implanted worldwide, REPER RPR-13 are Hydrophobic monofocal intraocular lenses, similar to normal hyrodphobic lenses manufactured, however the manufacturer REPER NN, being located in Russia and due to sanctions in Russia, the manuacturer is unable to obtain a free sale certificate in any GHTF Countries, hence this clinical trial to evaluate the safety and efficary of RPR-13 Intraocular lens,

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 90.00 Year(s)(—)
性别
All

入选标准

  • Adults, Subjects who have already undergone cataract surgery using IOL, Calculated IOL power is within the range of the investigational IOL (+ 10.0 to 30.0 Diopter), Subjects available after contact and willing to come for follow up during the clinical study, Subjects with signed informed consent, Subject having clear intraocular media other than cataract.

排除标准

  • Patients unwilling to participate in the study, subject with previous intraocular or corneal surgery, Subject having traumatic cataract, Pregnancy or lactation, Concurrent participation in another drug or device investigation, Instability of keratometry or biometry measurements, Irregular astigmatism.

结局指标

主要结局

To assess the intraoperative safety and performance of the Intraouclar Lens.

时间窗: 2 Months, 6 Months, 12 Months

次要结局

  • To determint the prescence of lens related adverse events, residual risks and visual acuity in the individuals on whom the device was implanted(2 months, 6 months, 1 year)

研究者

发起方
Rayner Surgical India Pvt Ltd formerly Surgicon Healthcare Pvt Ltd
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Uday Gajiwala

Tejas Eye Hospital

研究点 (1)

Loading locations...

相似试验

Post Marketing Clinical Study to Examine the safety... | 临床试验